Page last updated: 2024-11-08

l 685818

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 685818: structure given in first source; the C18-hydroxy, C21-ethyl analog of FK-506; binds to FKBP-12; antagonizes FK-506 and rapamycin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID445642
SCHEMBL ID14434002
MeSH IDM0205457

Synonyms (12)

Synonym
143839-74-1
l-685,818
18-hydroxyascomycin
l 685818
SCHEMBL14434002
(1r,9s,12s,13r,14s,17r,18e,20s,21r,23s,24r,25s,27r)-17-ethyl-1,14,20-trihydroxy-12-[(e)-1-[(1r,3r,4r)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetr
(3s,4r,5s,8r,9e,11s,12r,14s,15r,16s,18r,19r,26as)-8-ethyl-5,11,19-trihydroxy-3-{(e)-2-[(1r,3r,4r)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3h-15,19-e
Q27456805
HY-125693
l685818
CS-0093027
AKOS040752320

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" At present, it is unclear whether these immunosuppressive and toxic effects result from interference with related biochemical processes."( The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin.
Beattie, TR; Dumont, FJ; Harrison, R; Kindt, VM; Koprak, SL; Lin, CS; Sewell, T; Siekierka, JJ; Staruch, MJ; Wyvratt, M, 1992
)
0.28

Bioavailability

ExcerptReferenceRelevance
" The striking potency of these agents, their bioavailability and the dissociation of neurotrophic from immunosuppressant actions argue for their therapeutic relevance in the treatment of neurodegenerative diseases."( Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A.
Connolly, MA; Dawson, TM; Hamilton, GS; Hester, L; Snyder, SH; Steiner, JP; Valentine, HL, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves for TGF-beta-mediated signaling in primary fibroblasts and thymocytes isolated from either wild-type or FKBP12-deficient mice were identical."( FKBP12 is not required for the modulation of transforming growth factor beta receptor I signaling activity in embryonic fibroblasts and thymocytes.
Bassing, CH; Heitman, J; Matzuk, MM; Muir, S; Shou, W; Wang, XF, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (64.29)18.2507
2000's5 (35.71)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.46 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]